Trials / Completed
CompletedNCT00873353
Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients
An Open Non-randomized Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Tarceva in Combination With Capecitabine in Patients With Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Grupo Gallego de Investigaciones Oncologicas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine efficacy of the treatment with erlotinib in combination with capecitabine in patients with advanced pancreatic cancer.
Detailed description
This efficacy will be determined by objective response rate following RECIST criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | capecitabine + erlotinib | 6 cycles (3 weeks each one) of : * capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks * erlotinib (Tarceva®) 150mg/day, oral. Days: every days |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-08-01
- Completion
- 2010-08-01
- First posted
- 2009-04-01
- Last updated
- 2010-08-18
Locations
8 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00873353. Inclusion in this directory is not an endorsement.